Iterum Therapeutics plc (ITRM)
NASDAQ: ITRM · Real-Time Price · USD
0.7185
-0.0154 (-2.10%)
Oct 22, 2025, 10:20 AM EDT - Market open
Iterum Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Iterum Therapeutics stock has a target of 9.00, which predicts a 1,152.61% increase from the current stock price of 0.72.
Price Target: $9.00 (+1,152.61%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 8, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Iterum Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +1,152.61% | May 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +595.89% | Sep 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $5 | Strong Buy | Maintains | $6 → $5 | +595.89% | Aug 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +735.07% | Jun 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +735.07% | May 31, 2024 |
Financial Forecast
Revenue This Year
2.86M
Revenue Next Year
16.63M
from 2.86M
Increased by 482.25%
EPS This Year
-0.44
from -1.26
EPS Next Year
-0.09
from -0.44
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.9M | 18.4M | |||
| Avg | 2.9M | 16.6M | |||
| Low | n/a | 14.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 543.6% | |||
| Avg | - | 482.2% | |||
| Low | - | 418.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.35 | 0.11 | |
| Avg | -0.44 | -0.09 | |
| Low | -0.53 | -0.26 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.